Qualtrics, and Ortho ready to become public companies

Qualtrics, and Ortho ready to become public companies

Two IPOs are hitting the market today: Qualtrics, and Ortho Clinical Diagnostics

Full day ahead for the markets, as two companies are ready to become public. IPOs have once again taken center stage, and increased investor appetite has seen the Renaissance IPO ETF skyrocket 106.76% between Jan 2020 and Jan 2021.

Qualtrics

The Utah-based software company is prepared to go public, by offering 50.4 million shares which prices range from $27 to $29 apiece. If everything goes smoothly, Qualtrics will reach a market valuation of nearly $15 billion, significantly higher than its first IPO in November 2018 – when it had a market cap of $4.3 billion.

The IPO proceeds will be used to pay the $1.76 billion debt owed to SAP America – the company which in 2018 bought it for $8 billion.

Qualtrics will be available for trading on the Nasdaq under the ticker XM, and as underwriters will be Morgan Stanley and JP Morgan.

Ortho Clinical Diagnostics

The global leader of in vitro diagnostics and a pioneer in innovative laboratory testing and blood-typing solutions will go public today under the symbol OCDX on the Nasdaq Global Select Market.

Ortho will make available for purchase 76 million shares priced at $17 each, with the gross proceeds expected to reach $1,292 million. The net proceeds from the IPO will be used to repay various borrowings made under its dollar term loan facility, and for general corporate purposes, along with working capital.

As underwriters, the clinic named JP Morgan, BofA Securities, and Goldman Sachs, among others.

Stay updated with CAPEX.com!

Sources: bloomberg.com, prnewswire.com, investors.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com

JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.